Future treatments for DEB are expected to drive the sector’s growth. The global dermatological cell and gene therapy (CGT) ...

Zevaskyn won FDA approval upon Abeona’s second filing of a biologics license application (BLA) for the therapy.

Hundreds of people gathered in New Hartford Saturday morning for the 4th Annual Grateful for Graham 5k Run & Walk.

Patients with severe dystrophic epidermolysis bullosa, or EB, have skin so fragile, the slightest touch can lead to ...

In this week’s edition of The Prototype, we look at quantum computing for image recognition, a gene therapy using a patient’s ...

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

The University of Minnesota and M Health Fairview’s Rare Disease Center of Excellence recently received $500,000 from the ...

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

Abeona shares are trading higher on Wednesday on possible continued strength after the FDA announced approval for its gene ...

Abeona Therapeutics Inc.’s ABEO share price has surged by 6.60%, which has investors questioning if this is right time to ...

(NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in adults and children with recessive dystrophic ...